Effectiveness and safety of vedolizumab induction with or without budesonide in patients with moderately to severely active Crohn’s disease in Europe: a retrospective observational study
Abstract Background Vedolizumab (VDZ), a gut-selective anti-lymphocyte trafficking integrin antibody, is effective in treating patients with moderately to severely active Crohn’s disease (CD). In this study, we examined the real-world effectiveness and safety of induction therapy using VDZ alone or...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BMC
2023-11-01
|
| Colección: | BMC Gastroenterology |
| Materias: | |
| Acceso en línea: | https://doi.org/10.1186/s12876-023-03032-7 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|